Investigation of the effect of administration of Metformin before surgery on controlling postoperative hyperglycemia in non-diabetic patients

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20111212008384N9

Enrollment

176

Registered

2022-04-24

Start date

2020-03-20

Completion date

Unknown

Last updated

2022-05-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

blood suger.

Interventions

Intervention 1: Intervention group: It consisted of 88 patients receiving one metformin tablet (Merck Sante company, France) at a dose of 500 mg half an hour before surgery orally at a time. Blood glu

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Non diabetic patients ASA class I or II Candidate for orthopedic surgery in Imam Reza Hospital of Mashhad during 1399 solar year Ages 18 to 80 years

Exclusion criteria

Exclusion criteria: Prohibitions of metformin use, such as acute or chronic renal failure or injury, or a candidate for diagnostic procedures requiring the administration of a contrast agent before and 5 hours after surgery Dissatisfaction Allergy to metformin Patients with ASA above grade II Drug addicts Uncomplicated surgical complication Forcing to use hemodynamic support drugs at any stage of the study Use non-general anesthesia to perform the procedure Need re-surgical intervention in the first 24 hours Diabetic people

Design outcomes

Primary

Measure	Time frame
Blood suger. Timepoint: after surgery then every 6 hours for 24 hours. Method of measurement: Bs glocometr.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Arash Peivandi Yazdi

Mashhad University of Medical Sciences

PeivandiA@mums.ac.ir+98 51 1802 2677

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026